News
- December 30, 2008
- AMBRILIA BIOPHARMA SUBMITS A REQUEST FOR ARBITRATION AGAINST MERCK
- December 18, 2008
- AMBRILIA TAKES ADDITONAL COST-CUTTING ACTIONS AND EXPLORES ALTERNATIVE STRATEGIC OPTIONS TO ENHANCE SHAREHOLDER VALUE
- December 4, 2008
- Ambrilia Biopharma and ZBx Corporation Enter Into an Exclusive License Option Agreement for the Worldwide Rights to Ambrilia's PSP94 Technology for Prostate Cancer Diagnosis
- November 19, 2008
- Ambrilia Initiates Plan Aiming to Significantly Reduce its Operations in France
- November 14, 2008
- Ambrilia Reports Third Quarter 2008 Results
- October 1, 2008
- Ambrilia reports positive results for the second clinical Phase III study of its octreotide prolonged-release formulation C2L
- September 29, 2008
- Ambrilia prioritizes its divestment strategy and takes cost-cutting actions to extend cash
- September 17, 2008
- Ambrilia to present at BioContact 2008
- September 16, 2008
- Ambrilia expands its goserelin product offering with a novel one-month formulation
- September 10, 2008
- Ambrilia to present at the Sachs 8th Annual Biotech in Europe Investor Forum
- August 8, 2008
- Ambrilia reports second quarter 2008 results
- August 5, 2008
- Ambrilia to present at the Canaccord Adams 28th Annual Global Growth Conference
- July 31, 2008
- Ambrilia: second quarter 2008 results conference call and webcast
- July 28, 2008
- Ambrilia provides update on PPL-100 partnership with Merck & Co., Inc.
- July 21, 2008
- Ambrilia initiates Phase I/II clinical program of its novel goserelin formulation
- June 27, 2008
- Ambrilia announces executive departure
- June 19, 2008
- Ambrilia validates its targeted delivery technology for cancer in vivo
- June 13, 2008
- Ambrilia to present at BIO2008
- June 10, 2008
- Ambrilia unveils its complete antivirals portfolio and highlights progress made in the strategic plan execution
- June 10, 2008
- Ambrilia to present its new HIV Integrase Inhibitors at the International HIV Drug Resistance Workshop
- June 3, 2008
- Ambrilia: AGM Details
- May 14, 2008
- Ambrilia reports first quarter 2008 results
- May 14, 2008
- Ambrilia reports positive final Phase III results for its Octreotide formulation C2L
- May 13, 2008
- Ambrilia: Notice of conference call and media advisory
- May 9, 2008
- Ambrilia: Conference call and webcast details for the first quarter 2008 results
- April 30, 2008
- Ambrilia to present at BioFinance 2008
- March 24, 2008
- Ambrilia announces fiscal 2007 results and provides programs and milestones review
- March 18, 2008
- Ambrilia: Conference call and webcast for fiscal 2007 results and review of programs and milestones
- February 28, 2008
- Ambrilia announces the departure of Dr. Chandra J. Panchal, Executive Vice-President, Business Development, Licensing and IP
- February 5, 2008
- Ambrilia to present at the 10th Annual BIO CEO & Investor Conference 2008
- January 22, 2008
- Ambrilia reports positive Phase III preliminary results showing the safety and efficacy of its prolonged-release formulation of Octreotide
- January 21, 2008
- Ambrilia: Conference call and webcast for Octreotide Phase III results
